STIM Neuronetics

Neuronetics to Report Second Quarter 2020 Financial and Operating Results and Host Conference Call

Neuronetics to Report Second Quarter 2020 Financial and Operating Results and Host Conference Call

MALVERN, Pa., July 21, 2020 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders, today announced that it plans to release second quarter 2020 financial and operating results prior to market open on Tuesday, August 4, 2020. The Company will host a conference call to review its results at 8:30 a.m. Eastern Time the same day. The call will be concurrently webcast.

The conference call will be broadcast live in listen-only mode via a webcast on the Company’s investor relations website at . To listen to the conference call on your telephone, please dial (877) 472-8990 for United States callers or +1 (629) 228-0778 for international callers and reference confirmation code 9783274, approximately ten minutes prior to start time. The replay will be available on the Company's website for approximately 60 days.

About Neuronetics

Neuronetics, Inc. is a commercial-stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from psychiatric disorders. Our commercial product, the NeuroStar® Advanced Therapy System, is a non-invasive and non-systemic office-based treatment that uses transcranial magnetic stimulation, or TMS, to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The system is cleared by the United States Food and Drug Administration, or FDA, for the treatment of major depressive disorder in adult patients who have failed to achieve satisfactory improvement from prior antidepressant medication in the current episode.  NeuroStar is also available in other parts of the world, including Japan, where it is listed under Japan’s national health insurance. Additional information can be found at .  

Investor Contact:

Mark R. Klausner

Westwicke Partners

443-213-0501

Media Contact:

Gina Kent

Vault Communications

610-455-2763

EN
21/07/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Neuronetics

 PRESS RELEASE

Neuronetics Reports First Quarter 2025 Financial and Operating Results

Neuronetics Reports First Quarter 2025 Financial and Operating Results MALVERN, Pa., May 06, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc., (NASDAQ: STIM) (the “Company” or “Neuronetics”) a vertically integrated, commercial stage, medical technology and healthcare company with a strategic vision of transforming the lives of patients whenever and wherever they need help, with the leading neurohealth therapies in the world, today announced its financial and operating results for the first quarter of 2025. First Quarter 2025 Highlights First quarter 2025 revenue of $32.0 million, an 84% incr...

 PRESS RELEASE

Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)...

Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) MALVERN, Pa., May 05, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, today announced the granting of inducement awards of Restricted Stock Units representing a total of 4,500 shares of the Company’s common stock (RSUs) to three new non-executive employees. In accordance with NASDAQ Listing Rule 5635(c)(4), these awards ...

 PRESS RELEASE

Neuronetics to Report First Quarter 2025 Financial and Operating Resul...

Neuronetics to Report First Quarter 2025 Financial and Operating Results and Host Conference Call MALVERN, Pa., April 22, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, announced that it plans to release first quarter 2025 financial and operating results prior to market open on Tuesday, May 6, 2025. The Company will host a conference call to review its results at 8:30 a.m. Eastern Time the same day. The conf...

 PRESS RELEASE

Evernorth Health Services, a Cigna Company, Expands NeuroStar® TMS Cov...

Evernorth Health Services, a Cigna Company, Expands NeuroStar® TMS Coverage for Adolescents Struggling with Depression Policy update increases access for millions covered by Evernorth Health Services MALVERN, Pa., March 31, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a vertically integrated, commercial stage, medical technology and healthcare company with a strategic vision of transforming the lives of patients whenever and wherever they need help, with the leading neurohealth therapies in the world, announced that Evernorth Health Services, a wholly owned subsidiary of T...

 PRESS RELEASE

Neuronetics Reports Updated Fourth Quarter and Full Year 2024 Financia...

Neuronetics Reports Updated Fourth Quarter and Full Year 2024 Financial and Operating Results MALVERN, Pa., March 27, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM) (the “Company” or “Neuronetics”) is issuing this press release to update the reporting of its financial results for the fourth quarter and full year ending December 31, 2024. Following the Company’s press release on March 4, 2025 initially issuing the Company’s fourth quarter and full year 2024 financial results (the “Initial Release”) and in connection with finalizing the audited financial statements for the fiscal...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch